Investment Test Drive

PJHRX Prudential Jennison Health Sciences R

6 lower fee alternatives found

FeeX scanned the market for similar funds with lower fees and better past returns
Show results with
Fund PJHRX Prudential Jennison Health Sciences R BBH VanEck Vectors Biotech ETF XBI SPDR® S&P Biotech ETF  
100% 93% 92%
Annual Fees
(1.33% Exp. Ratio)
(0.35% Exp. Ratio)
(0.35% Exp. Ratio)
Future Est. Balance in 30 yrs
Assuming 5.73% annual return
$35,622.35 $47,916.81 $47,916.81
Est. savings over 30 yrs +$12,294.45 +$12,294.45
As of 9/30/16
1 YR RETURN -5.08%
3 YR 10.49%
5 YR 22.82%
10 YR 13.84%
1 YR RETURN 0.97%
3 YR 11.78%
5 YR --
10 YR --
1 YR RETURN 6.97%
3 YR 16.26%
5 YR 27.90%
10 YR 16.38%
The investment seeks long-term capital appreciation. The fund seeks investments whose price will increase over time. The fund normally invests at least 80% of its investable assets in equity and equity-related securities of companies within the health sciences sector, such as pharmaceutical companies, biotechnology companies, medical device manufacturers, healthcare service providers and health maintenance organizations (HMOs) and other companies that derive at least 50% of their assets, revenues or profits from operations in the healthcare sector. The fund is non-diversified.
The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.

Join FeeX to view all alternatives, get more data and filtering options, and be able to automatically scan all your investments for lower fee replacements.

It's free!

The fees, balance and savings information above are estimated numbers, based on the data FeeX had at the day of publication, but may not be accurate due to incomplete or erroneous data.

The best choice is based on a combined analysis of lowest fees and highest similarity to the original fund.


FeeX's similarity algorithm analyzes over 15 investment characteristics like investment category, asset allocation, strategy, geographical allocation and more. FeeX gives each its own weight and calculates the similarity of any two investments based on a scale of 0 to 100%. Funds with a similarity ranking of 85% and higher are considered "similar".

Yes, funds and ETFs charge fees

Deep within every fund you own lies a hidden fee called expense ratio. It takes away a set % of your savings each and every year. It can often be easily reduced by switching to similar investments with lower expense ratios.


Your Feedback has been sent successfully!